Obesity drugs linked to lower sudden cardiac death risk
Drug users had a lower relative risk of sudden cardiac death than nonusers over five years, with a hazard ratio of 0.45.
Our read
Interventions- Studied:
- Cohort study of 149,858 adults with morbid obesity per group, 5 years, against nonusers
- What changed:
- Sudden cardiac death risk was lower among drug users than nonusers (hazard ratio 0.45)
- The catch:
- Drug users and nonusers could differ in health or care despite matching
- In the record:
- The 1,361st paper on GLP-1 receptor agonists with results in people; 4,739 on record in all. Its result on mortality agrees with 184 of 204 other findings on record; 1 points the other way and 19 found no change.
- Why it’s aging research:
- It studies an intervention with evidence of extending healthy life.
Editor of record: Boris Djordjevic · AgingResearch.News
Adults aged 18–45 with morbid obesity, defined as a body mass index of at least 40, were compared in a retrospective cohort study of health records. The researchers matched 149,858 users of liraglutide, semaglutide, exenatide or tirzepatide with 149,858 nonusers.
Over five years, use of these drugs was associated with a lower risk of sudden cardiac death. The hazard ratio, a relative measure comparing risk over time, was 0.45. Drug use was also linked to lower risks of dangerous heart rhythms in the heart’s lower chambers, heart attacks and death from any cause. The association with lower sudden cardiac death risk appeared in both sexes and in people with and without diabetes.
Why it matters
Premature mortality in young adults with severe obesity makes cardiovascular health a concern for healthy aging well before old age.
Caveats
Drug users may have differed from nonusers in health or care in ways matching did not capture. The conference abstract gives no absolute event rates, and the findings do not address older adults or people with less severe obesity.
The paper
Beyond Weight Loss: GLP-1 Receptor Agonists and Risk of Sudden Cardiac Death in Morbid Obesity
John A. Burns Sch of Medicine; Saint Louis Univ Sch of Medicine
AHA Scientific Sessions 2026 Abstract, Nov 2, 2026
Presented at AHA Scientific Sessions 2026, abstract 16420
Comments
Be the first to comment.